Sensei Biotherapeutics (SNSE) Stock Price, News & Analysis

Company Overview

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $0.46 to $0.53
• 50-Day Range: $0.42 to $0.78
• 52-Week Range: $0.38 to $1.94
• Volume: 440,578 shs
• Average Volume: 196,936 shs
• Market Capitalization: $12.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.33
• Consensus Rating: Buy

Sensei Biotherapeutics Stock Analysis - MarketRank™

Sensei Biotherapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 82nd out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sensei Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sensei Biotherapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Sensei Biotherapeutics are expected to remain at ($1.11) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sensei Biotherapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sensei Biotherapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sensei Biotherapeutics has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sensei Biotherapeutics does not currently pay a dividend.

Dividend Growth

Sensei Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.38

Percentage of Shares Shorted

1.18% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.60

News Sentiment

Sensei Biotherapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Sensei Biotherapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for SNSE on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.50% of the stock of Sensei Biotherapeutics is held by institutions.

SNSE Stock Analysis - Frequently Asked Questions

How have SNSE shares performed this year?

Sensei Biotherapeutics' stock was trading at $0.6920 at the start of the year. Since then, SNSE stock has decreased by 28.0% and is now trading at $0.4980.
View the best growth stocks for 2024 here.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01.

When did Sensei Biotherapeutics IPO?

Sensei Biotherapeutics (SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

Who are Sensei Biotherapeutics' major shareholders?

Top institutional investors of Sensei Biotherapeutics include National Bank of Canada FI (0.18%). Insiders that own company stock include John Celebi, Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer and Thomas G Ricks.
View institutional ownership trends.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sensei Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SNSE
• CUSIP: N/A
• CIK: 1829802
• Web: www.senseibio.com
• Phone: 240-243-8000
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.33
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +770.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-34,100,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.86%
• Return on Assets: -46.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.84
• Quick Ratio: 8.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.60 per share
• Price / Book: 0.19

Miscellaneous

• Outstanding Shares: 25,151,000
• Free Float: 19,618,000
• Market Cap: $12.53 million
• Optionable: Not Optionable
• Beta: 0.06